Company performance
Add to research
Current Price
as of Mar 25, 2025$120.36
P/E Ratio
N/A
Market Cap
$5.87B
Description
Add to research
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Metrics
Add to research
Overview
- HQNew York, NY
- SectorHealth Technology
- IndustryBiotechnology
- TickerAXSM
- Price$120.36-6.82%
Trading Information
- Market cap$5.87B
- Float82.18%
- Average Daily Volume (1m)607,994
- Average Daily Volume (3m)974,060
- EPS-$5.99
Company
- Revenue$385.69M
- Rev growth (1yr)42.53%
- Net income-$287.22M
- Gross margin89.30%
- EBITDA margin-63.39%
- EBITDA-$244.48M
- EV$3.94B
- EV/Revenue10.22
- P/EN/A
- P/S14.95
- P/B62.75
- Debt/Equity355.89
Documents
Add to research
SEC Filings
Factset Street Account